U.S. budgets $1B to fuel swine flu research

With new swine flu fatalities being reported in the U.S., Canada and Mexico, the U.S. government has decided to dole out a billion dollars to a group of major vaccine manufacturers to fuel the rapid development of a new vaccine.

Novartis led the pack with $289 million in federal support, followed by Sanofi Aventis with $191 million and GlaxoSmithKline, which gets $181 million. The money will fund clinical tests on a new A/H1N1 vaccine this summer followed by the stockpiling of primary ingredients for a new vaccine, in case the U.S. triggers a multibillion-dollar immunization campaign in the fall.

On Monday, Sanofi said that the U.S. order was "the first of what is expected to be a series of orders." Sanofi, which manufactures vaccines in Pennsylvania and France, added that it is also in discussions with other governments around the world.

The U.S. strategy will de-risk the companies' vaccine development plans, providing the funds for developing a new jab that may never be used. But as new deaths grab headlines around the world, it appears increasingly likely that the vaccine industry will roll out a three-shot vaccine series to guard against swine flu as well as seasonal flu.

- read the report from the Wall Street Journal
- read the story from the Canadian Press
- read the story from Bloomberg on the spread of swine flu

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.